Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia.
Sign Up to like & getrecommendations! Published in 2018 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2017.0734
Abstract: Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia To the Editor We read with interest the article outlining the 2016 mSMART guidelines for the diagnosis and management of Waldenström macroglobulinemia (WM).1 We believe… read more here.
Keywords: rituximab; management waldenstr; waldenstr macroglobulinemia;
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25961
Abstract: We analyzed 160 young Waldenström Macroglobulinemia (WM) patients with a median age of 49 years (range 23‐55 years), diagnosed between January 2000 and January 2019 in 14 Italian centers. At diagnosis, 70% of patients were asymptomatic. With… read more here.
Keywords: waldenstr macroglobulinemia; risk; immunotherapy; high risk ... See more keywords
Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: correlations and prognostic impact.
Sign Up to like & getrecommendations! Published in 2021 at "American journal of hematology"
DOI: 10.1002/ajh.26339
Abstract: While Waldenström macroglobulinemia (WM) is characterized by an almost unifying mutation in MYD88, clinical presentation at diagnosis and response to therapy can be widely different among WM patients. Current prognostic tools only partially address this… read more here.
Keywords: waldenstr macroglobulinemia; impact; cytogenetic molecular; molecular abnormalities ... See more keywords
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26788
Abstract: Bruton tyrosine kinase (BTK) inhibitors have taken a central role in the management of patients with Waldenström macroglobulinemia and are the only agents approved by the Food and Drug Administration (FDA) to treat these patients.… read more here.
Keywords: bruton tyrosine; management; tyrosine kinase; waldenstr macroglobulinemia ... See more keywords
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26796
Abstract: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. read more here.
Keywords: waldenstr macroglobulinemia; macroglobulinemia 2023; update diagnosis; waldenstr ... See more keywords
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.2982
Abstract: The pivotal role that ibrutinib plays in the management of Waldenström macroglobulinemia (WM) is undisputed but there are ongoing questions regarding its positioning in the therapeutic algorithm of WM as well as in some peculiar… read more here.
Keywords: use btk; ibrutinib; waldenstr macroglobulinemia; panel ... See more keywords
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34405
Abstract: Waldenström macroglobulinemia (WM) is a rare subtype of non‐Hodgkin lymphoma characterized by malignant lymphoplasmacytic cells in the bone marrow (BM). To dissect the pathophysiology of WM, we evaluated clonal cells by mapping of B cell… read more here.
Keywords: waldenstr macroglobulinemia; tumor microenvironment; innate adaptive; adaptive immune ... See more keywords
Waldenström's macroglobulinemia masquerading as ovarian cancer with peritoneal carcinomatosis, ascites, and elevated CA-125.
Sign Up to like & getrecommendations! Published in 2019 at "Hematology/oncology and stem cell therapy"
DOI: 10.1016/j.hemonc.2017.02.004
Abstract: Waldenström's macroglobulinemia is a rare hematology malignancy which often presents with "B symptoms," anemia, and thrombocytopenia. A 46-year-old woman presented with 2 months of abdominal distension accompanied by an unintentional 20-lb weight loss. Her abdominal… read more here.
Keywords: waldenstr macroglobulinemia; waldenstr; hematology; carcinomatosis ... See more keywords
Familial Waldenström Macroglobulinemia: Families Informing Populations.
Sign Up to like & getrecommendations! Published in 2018 at "Hematology/oncology clinics of North America"
DOI: 10.1016/j.hoc.2018.05.006
Abstract: Familial clustering of Waldenström macroglobulinemia (WM) has been observed for nearly 6 decades. Family studies have provided seminal observations in delineating the phenotypic spectrum of WM susceptibility and confirming the importance of immunoglobulin M (IgM)… read more here.
Keywords: waldenstr macroglobulinemia; waldenstr; familial waldenstr; macroglobulinemia families ... See more keywords
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Sign Up to like & getrecommendations! Published in 2018 at "Hematology/oncology clinics of North America"
DOI: 10.1016/j.hoc.2018.05.012
Abstract: Waldenström macroglobulinemia (WM) is an indolent B-cell lymphoma that is heavily dependent on Bruton tyrosine kinase (BTK) hyperactivation. Ibrutinib is a first-generation BTK inhibitor that has shown high activity and durable responses in patients with… read more here.
Keywords: first generation; waldenstr macroglobulinemia; generation; second generation ... See more keywords
PCN168 GLOBAL BURDEN OF WALDENSTRÖM MACROGLOBULINEMIA (WM): A SYSTEMATIC LITERATURE REVIEW (SLR) AND EVIDENCE GAP ANALYSIS
Sign Up to like & getrecommendations! Published in 2019 at "Value in Health"
DOI: 10.1016/j.jval.2019.04.292
Abstract: RESULTS: Of 1146 evaluable publications, 51 were included based on above search criteria. WM incidence ranged from 0.3-0.57/100,000 person-years in US studies, with most data showing decreased or stable incidence over time. WM incidence appeared… read more here.
Keywords: global burden; waldenstr macroglobulinemia; burden; burden waldenstr ... See more keywords